News
Agomab Therapeutics NV (‘Agomab’) today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback